glp 1 agonist cardioprotective Frontiers Upcoming wave of hormone-based therapies

Following the predefined inclusion and exclusion criteria, 36 studies were included in this systematic review and underwent qualitative analysis

Although dedicated trials of GLP-1RAs in AITD are lacking, preliminary reports suggest potential impacton thyroid volume, thyroid function, and autoimmune activity

Partly through these actions, GLP-1 receptor agonism was shown to reduce cardiovascular disease (CVD) in people with T2D with previous CVD or at high-risk thereof

Specifically, the trial reported an average weight loss of 17.5% and 24.4% at 24 and 48 weeks, respectively

It seems like asking someone to stay on a weekly injection indefinitely is a much harder sell